Corporate Member Roster

We are a different kind of PBM and a different kind of company. Our entire organization has a culture of accountability, a sense of urgency, and an unstoppable commitment to finding a better way. Abarca has deep experience serving public and private sector organizations, including: Medicare and Commercial Health Plans, Self Insured Employers, State Medicaid Programs, and Large Insurers and PBMs. Americans are spending nearly half a trillion dollars every year on prescription benefits. It’s a system that isn’t working for payers, members, or providers. It doesn’t need to be this way. We believe costs should be lower, hassles should be fewer, and the experience should be better. And with a smarter technology and a straightforward approach to business, we are ready to lead the way.

Through a steadfast commitment to research, technology and state-of-the-art manufacturing, Abbott has developed a diverse portfolio of breakthrough diabetes products designed to meet the needs of each unique patient. Our innovative product development program is responsible for several groundbreaking technologies. Keep looking to our dedicated teams for the next generation of highly innovative and effective glucose monitoring products. We aim to set the standard for helping patients and healthcare providers to potentially achieve the best health outcomes.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders. Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. ADC Therapeutics has a deep understanding of antibody drug conjugate technology and the oncology treatment landscape. The company is dedicated to efficiently progressing its potential best-in-class PBD-armed ADCs to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).

Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious and rare diseases. Our priority is to bring transformative medicines to patients by driving clinical program execution, understanding patient and physician needs, preparing the market, creating market access, and commercializing our products on a global basis. We are driven by the knowledge that patients depend on us. Akcea, an affiliate of Ionis Pharmaceuticals, was established in early 2015 and based in the Seaport District in Boston, Massachusetts. Akcea has a robust portfolio of development- and registration-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Ionis standards of excellence.

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent.

As a world leader in allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).

Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription.

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.The world’s largest biotechnology company, Amgen Inc. discovers, develops, and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept), Kineret® (anakinra) and Sensipar® (cinacalcet HCl). Amgen’s dedication to science and innovation is driven by a commitment to serving patients.

We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Ascendis Pharma is applying its innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.

Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Our mission is to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. To achieve this, we have assembled an experienced leadership team and have established global operations across the pharmaceutical value chain.

Avalere Health is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers.

Aventine is a consulting firm specializing in the development of formulary submission dossiers and economic modeling and comprised of a strategic team of highly experienced managed care pharmacists who understand the needs of the payer audience. Our team leverages our past professional experience on the payer side of the access equation to create dossiers and models that are fit for purpose. We develop scientifically-sound, evidence-based, high-quality deliverables supporting the true value of our clients’ products and have decades of experience communicating to the US payer audience. Our team prides itself on the integrity of our work, the trusted relationships we have forged with our clients, and our high rate of returning customers. Since Aventine’s inception in 2008, our strong reputation as a personable and accountable boutique consulting firm has become one of our greatest professional assets. Ask around – our active client base includes companies of all sizes: from small start-ups, to biotechs, to large pharma companies in the top 5 by global sales revenue.

BD is a leading global medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. The company focuses strategically on achieving growth in three worldwide business segments - BD Medical, BD Diagnostics and BD Biosciences. BD employs approximately 29,000 associates worldwide in 212 locations in 50 countries. For the fiscal year ended September 30, 2010, BD's revenues rose to $7.372 billion. BD was founded as a partnership in 1897 and incorporated in 1906. BD became a publicly held company in 1962. The stock is traded on the New York Stock Exchange with the symbol BDX. BD is dedicated to producing solutions - and the best solution of all is reflected in its corporate purpose, helping all people live healthy lives.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.

Our mission is to partner with the health care community to help people resume and enjoy active lives. To this end, we develop and/or market clinically proven and cost-effective orthobiologic solutions for bone fusion and osteoarthritis that are backed by clinical data. Thousands of physicians worldwide view their Bioventus representative as an extension of their practices, trusting them with helping in their patients’ care program and alleviating some of their administrative burdens. Bioventus’ adherence to high quality standards, its commitment to evidence-based medicine and its strong ethical behavior makes the company a trusted partner.

At bluebird bio, we’re pushing hard on gene therapy because we believe it delivers the chance for people with severe genetic diseases and cancer to live fully, regardless of what’s written in their DNA. We’re doing the hard work because people facing these challenges deserve it. Our goal is to recode the science, the system – and even the status quo – for life. We are 1,100+ employees across the US & Europe who care deeply and challenge convention to help the people who need us. We are working toward four potential product approvals by 2022 and a pipeline ready to tackle a range of severe diseases. Powered by multiple labs, in-house lentiviral vector manufacturing capabilities and future drug product production, we push ourselves to find answers for the people who need them by exploring the cutting-edge spectrum of gene therapy.

Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales. As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Our company’s mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products. We pledge – to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve – to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker. Aligned with our mission, Bristol-Myers Squibb Managed Markets team is dedicated to supporting the important role managed care plays in extending and enhancing human life.

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.

Confidio is a technology enabled pharmacy benefits management consultancy, focused on the highly specialized areas of managed prescription drug benefits, programs and services. We go beyond the expected to optimize financial & clinical outcomes of prescription drug therapies with sustainable solutions you can trust. Confidio offers a robust solution suite of consulting services and solutions including PBM Vendor Procurement and Contracting, Vendor Management and Oversight, Strategic Pharmacy Consulting, Auditing & Contract Compliance, Pharmacy Plan Design, Clinical Optimization, Government Program Support and Advanced Data Analytics and Reporting. In addition, Confidio offers a turn-key solution called Performance Pharmacy SolutionsTM (PPS). PPS is a leveraged contract solution, that would most closely align with a benefit purchasing coalition for middle market benefit advisors (brokers, consultants and TPAs), to negotiate competitive pricing and contract terms for groups with

CVS is headquartered in Woonsocket, RI, the largest pharmacy health care provider in the U.S. and has integrated offerings across the spectrum of pharmacy care that involves more than 246,000 colleagues across all 50 states, Washington, D.C., Puerto Rico and Brazil. Millions of times a day, we’re helping people on their path to better health—from advising on prescriptions to helping manage chronic and specialty conditions. Because we’re present in so many moments, big and small, we have an active, supportive role in shaping the future of health care

We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo’s research and development is Oncology The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.

Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes

At Dicerna, we create medicines that selectively silence the genes that cause disease using RNA interference, or RNAi. We are leaders in RNAi, harnessing the potential of this powerful and complex process to create medicines that can enhance the health and extend the lives of patients with rare diseases and common diseases that have a genetic component. Genes play a primary role in thousands of diseases. At Dicerna, we use our proprietary GalXC™ platform to develop safe and potent RNAi therapies that target and suppress genes. We are advancing our growing pipeline of product candidates designed to inhibit the genetic causes of diseases and disorders that affect the liver, kidney, cardiovascular system and central nervous system.

Satisfying diverse healthcare needs around the world ~ Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities.

EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.

Epizyme’s vision is to rewrite treatment for cancer and other serious diseases through novel epigenetic medicines. We aspire to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. At Epizyme, our exceptional team is wholly dedicated to bringing epigenetic therapies to the many patients who can benefit from them. We believe that we have the opportunity to change the lives of patients living with cancer and other serious diseases and are well positioned to deliver on our multi-year vision.

We set our sight on a simple, but powerful vision to advance life science services toward a healthier world. The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA. We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of urology, gynaecology & obstetrics, gastroenterology and endocrinology. The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors combat numerous diseases and medical conditions. The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world. In recent years Ferring has expanded beyond its traditional European base. It now has offices in over 40 countries employing over 2,700 people, and its treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades. Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients.

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Survival rates are higher when cancer is diagnosed at earlier stages. However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower. We believe we are taking on one of the biggest challenges of our lifetime, combining science, technology, and population-scale clinical studies to reveal cancer at its beginnings. To detect cancer early, when it can be cured. At GRAIL, we find purpose in our mission and call on our passion as we tackle one of the most important problems in the world.

Greenwich Biosciences is the US leader in the field of cannabinoid prescription medicines.Our mission is to lead the world in developing and commercializing regulatory approved cannabinoid medicines, putting patients first We created the first-ever controlled clinical trial program evaluating a cannabinoid medicine, for patients with Dravet syndrome and Lennox-Gastaut syndrome (LGS). Our products are backed by science, independently vetted, FDA-approved, and consistently manufactured—because we believe no cannabinoid should go to market without the data evaluating its safety profile, efficacy, and its potential to help.

GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.

Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, our goal is to push the boundaries of what science can do to improve the lives of patients. Our primary mission is to have a positive impact on the lives of those who are so often underserved. We believe it takes both scientific vision and tenacity to pursue new therapies that will have the potential to transform the lives of patients.

At Horizon, we define our success by a different set of numbers: the number of lives touched, the number of lives changed, the number of lives saved. As we build a growing pipeline and explore all potential uses for our medicines, we strive to make a powerful difference for our patients, their caregivers and physicians every day. Our drive to deliver breakthrough therapies comes from our deep understanding of the patient journey. These patients’ courage inspires us – and drives us to listen, collaborate and build communities. That’s why, at our core, we believe science and compassion must work together to transform lives.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing our proprietary bile acid chemistry. The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

Ipsen is a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology , neuroscience and rare diseases. Ipsen’s mission, “innovation for patient care”, highlights the Group’s determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. As well as our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate. The Group is pledged to promote ethical, responsible and transparent professional practices.

Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Kiniksa is a biopharmaceutical company with an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most.

Kroger Prescription Plans has provided comprehensive Pharmacy Benefits Management services since 1993. We combine transparency and highly competitive pricing to drive lower costs for clients and their members, while at the same time delivering exceptional customer service. Our plans are flexible and adaptable. Kroger Prescription Plans is focused on improving the health & wellness of our customers. We are committed to advancing health, reducing costs and improving the efficacy of any client’s health strategy.

LEO Pharma Inc. is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology. LEO Pharma products have been available in the U.S. since 1994, and the company opened the U.S. affiliate in January 2010. The company's U.S. offices are located in Madison, N.J. LEO Pharma has a 100+ year history as a specialty pharmaceutical company, committed to the discovery and development of novel drugs for patients; markets products in 100+ countries worldwide; employs 6,000 dedicated colleagues operating across 61 countries, and remains wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark, outside Copenhagen.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

At Magellan Rx Management, we are a full-service pharmacy benefits manager (PBM) that specializes in solving complex pharmacy challenges for our customers. We believe in developing and executing smart solutions that leverage our industry-leading experience and technology to exceed expectations across the following lines of business: Employer, Third Party Administrator, Broker; Managed Care; Government, Medicaid, Medicare Part D. As a pioneer in medical specialty pharmacy management and a leader in best-in-class formulary optimization programs, we deliver consistent, proven cost savings. As clinical experts, we deliver customized programs to address our clients’ most pressing clinical challenges, drive STAR improvements, and engage patients and providers to deliver improved health outcomes. elcome to a unique vision of care. Magellan Rx Management is a division of Magellan Health, Inc.

Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.

MedImpact is the PBM that puts clients and consumers first. For 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and transparent. Today, MedImpact’s team and technology serve many large employers and plans, and more than 55 million consumers in the US and around the world. Learn more at medimpact.com or follow us on Twitter @MedImpact.

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

MHK’s mission is to drive better member care in a changing healthcare environment by bringing every care moment in a person’s health journey together through an integrated platform. Founded in 2010 on the concept that healthcare reimbursements would be tied to quality versus fee-for-service—a precursor to today’s value-based healthcare, MHK continues to push the envelope to ensure increased efficiencies that save time and money, and ultimately, enhance health outcomes. Our vision is to build the trusted care management solutions of tomorrow to revolutionize the way healthcare is delivered.

Independent for over 70 years, Milliman delivers market-leading services and solutions to clients worldwide. With no agenda, other than getting it right.Through a team of professionals ranging from actuaries to clinicians, technology specialists to plan administrators, we offer unparalleled expertise in employee benefits, investment consulting, healthcare, life insurance and financial services, and property and casualty insurance.

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.

Since 1991, Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. More than 1.5 million patients have already benefited from Myriad’s hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Today, Myriad continues this strong tradition. We are expanding our reach and increasing our impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.

The health care environment is becoming more complex, with commercial and government payers attempting to control how health care is practiced and influence market perceptions about products, coverage, or services. NaviSync is a full-service managed markets company providing intelligent sound strategy to increase access to your brand through the utilization of actionable insights gleaned from payers, hospitals, and alternative care settings. Efficiently delivered market intelligence is critical to attaining payer access and achieving commercial success. We tackle access and reimbursement challenges for top-tier pharmaceutical/biotechnology companies, including specialty market products.

Neurelis is a unique company focused on therapies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to successfully deliver innovative therapies that have the potential to change the lives of patients, caregivers, and healthcare providers. Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.

AveXis is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases

Novartis Pharmaceuticals Corporation is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative, effective and safe prescription medications. Key therapeutic areas include Cardiovascular, Endocrine & Respiratory Diseases, Gastroenterology; Central Nervous System Disorders; Dermatology; Oncology/Hematology; Rheumatism/Bone & Hormone Replacement Therapy and Transplantation. Located in East Hanover, NJ, Novartis Pharmaceuticals is an affiliate of Novartis AG, a world leader in Healthcare in more than 140 countries with core businesses in pharmaceuticals, consumer health, generics, eyecare, and animal health.

Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.

The Optinose team is unified by a common shared mission: to improve lives. We will accomplish this while creating value for investors and the healthcare system along with better outcomes for patients and providers. As innovators in every aspect of our work, we will pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient. We are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a foundation for future success.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).

PerformRx? is an NCQA and URAC-accredited, next-generation pharmacy benefits manager located in Philadelphia, PA. Formed in 1999, PerformRx maintains a clinical culture, providing cost-effective therapies and extensive evidence-based programs at an optimal cost to its clients. PerformRx’s best-in-class pharmacy benefit management services include formulary development, drug therapy management and rebate management. PerformSpecialty® is PerformRx’s wholly-owned and integrated specialty pharmacy. Markets serviced by PerformRx include Medicaid, Medicare, commercial and employer group.

As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development. We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most. The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.

We are your advocate in drug management. For over 25 years PSG has been singularly focused on helping our clients navigate the complex and ever-changing challenges of drug management. Through our leading pharmacy intelligence and technologies, we save our clients billions of dollars every year with an unwavering commitment to serving as your advocate and strategic partner. Our mission is to relentlessly advocate for our clients as we partner together to develop innovative drug management solutions that deliver exceptional insights, financial and clinical value.

Pharmacy Quality Solutions (PQS), is the leading provider of performance management services representing nearly 80% of Medicare Advantage payers and 95% of community pharmacies. PQS delivers the quality insights and guidance necessary to support its customers’ efforts to optimize the quality of medication management and use for their Medicare, Medicaid and commercial populations. PQS connects medication use stakeholders to actionable, quality information in a consistent and reliable fashion, allowing them to move more quickly from measurement to improvement. Its industry-leading platform, EQuIPP™, provides dependable measurement and reporting on key medication use quality measures, including addressing medication adherence, gaps in care, and patient safety. PQS provides measurement insights that are timely, actionable, and simply understood.

Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry. Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics.

Prime Therapeutics is an independent pharmacy benefit manager that is committed to the health of those we serve. Our "people over profits" approach reflects our privately held heritage. We also believe it produces the best results. Our health care system is fragmented. Instead of working together, doctors, pharmacists, and insurers often focus only on their own pieces of the puzzle. Poor communication and lack of coordination cause errors and create gaps in care. Prime has a different view. Because we are collectively owned by non-profit health plans, we never forget that drugs are part of a bigger picture. We exchange pertinent data and insights with health plans and work with them to coordinate across pharmacy and medical benefits. We leverage our unique connections to deliver programs that lead to the best health outcomes.

The lives of patients and their families are the primary motivators at Provention Bio. Before they become patients for life, before their days are cut short, we look to intervene by researching, developing, and bringing medicines to market that have the potential to intercept and prevent autoimmune diseases that would have otherwise robbed them of their full lifetime of potential. We are aiming to bring novel medicine to practice through ingenious science and unrelenting partnerships so that together we can change the world.

Purdue Pharma L.P. develops and provides prescription medicines that meet the evolving needs of healthcare professionals, patients, and caregivers. We were founded by physicians and we are currently led by a physician. Beyond our efforts to provide quality medications, Purdue is committed to supporting national, regional and local collaborations to drive innovations in patient care. Privately held, Purdue is pursuing a pipeline of new medications and technologies through internal research & development and strategic industry partnerships.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

RxAnte is a leading predictive analytics and clinical services company located in Portland, Maine, and Washington, D.C., dedicated to improving medication use and health outcomes. By providing plans, providers, and manufacturers with actionable insights, strategies, and our own portfolio of interventions, RxAnte empowers clients with the resources necessary to help make medications work better for everyone.

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage is thinking differently about drug development by using a focused, practical and deliberate approach. We responsibly pursue expedited pathways in our efforts to deliver new treatments for CNS disorders. At Sage, our mission is to make life better for patients with CNS diseases by discovering, developing, and delivering important new medicines for patients in need.

Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.

Scipher Medicine holds the fundamental belief that patients deserve simple answers to their treatment options using scientifically backed data. With artificial intelligence and its proprietary molecular technology platform, Scipher Medicine develops innovative diagnostic tests that predict which drug will work from day one and use the data from these tests to develop more effective therapies to improve patient outcomes.

Seagen Inc.is a global biotechnology company that discovers, develops and commercializes transformativecancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For moreinformation on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal onTwitter.

Sobi is an international rare disease company dedicated to providing access to innovative treatments that make a significant difference for people with rare diseases. Strong and growing portfolio: We have two busienss areas: Haemophilia and Specialty Care. Our research and product portfolio is primarily focused on hemophilia, inflammation, and genetic and metabolic diseases. In Hemophilia, we aim to take a leadership position. Sobi is an integraterd biotechnology company with in-house capabilities that encompass the entire value chain, from research to preclinical and clinical development, biologis manufacturing and supply, to patient access and distribution. This integrated approach is a prerequisite for providing proprietary drugs, and an enabler for partnerships, especially at early stages of drug development.

At Sunovion, patients are at the center of everything we do. We are creating innovative psychiatric, neurological and respiratory therapies that help transform people's lives, while at the same time we are playing an increasingly active role in the future of global health. Our Mission is to broadly contribute to society through value creation based on innovative research and development activities for the betterment of health care and fuller lives of people worldwide. Our Vision is to lead the way to a healthier world and Our Values are to serve and create value for patients; act with the highest standards; trust and empower our people; align, collaborate and win as one team.

With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Tabula Rasa HealthCare (TRHC) provides new beginnings for our clients, through innovative service models and fresh approaches to healthcare. TRHC provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens. We improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. We deliver our solutions through a comprehensive suite of technology-enabled products and services for medication risk management and risk adjustment.

Taiho Oncology, Inc. a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.

Based in Deerfield, IL, Takeda Pharmaceuticals, U.S.A., Inc and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, respiratory and immunology, gastroenterology, central nervous system and obesity treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, central nervous system, oncology and other conditions.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules, sold in more than 100 countries, and with a direct presence in about 60 countries. Teva's specialty medicine businesses focus on CNS, respiratory, and oncology therapeutic areas as well as biologics. Teva currently employs approximately 43,000 people around the world and reached $18.8 billion in net revenues in 2018.

TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. TOLMAR has 24 FDA-approved products.

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.

UCB's ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders - putting patients at the center of our world. We are Inspired by Patients. Driven By Science. UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions - so that they and their carers can get on with their lives.

Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals’ lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders.

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology. Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients.

Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigm and work to improve patient lives through discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches.

For more than 25 years, life science and biotech companies have turned to Xcenda’s leading team of value experts, transforming evidence, policy insights, and market intelligence into effective global market access strategies. Founded in the application of health outcomes and reimbursement, Xcenda, a part of AmerisourceBergen, is a premier consultancy helping clients effectively navigate today’s complex healthcare landscape. Our bench of diverse experts shares a passion to help you deliver the most distinctive body of evidence that demonstrates your value story. We strategically execute on actionable insights and differentiating data. We create innovative communications, models and tools so stakeholders understand not only what you’ve created, but why. It’s our goal to help prove the inherent worth of your products and services, maximize patient access, and enhance your overall brand performance. Trust in our committed team so you can focus on what matters most—helping patients gain access to your brand. Learn more at Xcenda.com.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.